Señales en vivo de MNK | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 ago 2023 @ 16:00):

Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally...

Stats
Volumen de hoy	543 145
Volumen promedio	3.71M
Capitalización de mercado	4.52M
EPS	$0 ( 2024-03-19 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.436
ATR14	$0.224 (224.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-05	Goldentree Asset Management Lp	Buy	75 000	Ordinary Shares
2023-12-04	Goldentree Asset Management Lp	Buy	0	Ordinary Shares
2023-11-14	Zinman Jon	Buy	0
2023-11-14	Stetson David J.	Buy	0
2023-11-14	Bracebridge Capital, Llc	Buy	1 093 857	New Common Stock

INSIDER POWER
-27.52
Last 92 transactions
Buy: 3 785 978 \| Sell: 4 853 818

Volumen Correlación

Largo: 0.17 (neutral)

Corto: -0.66 (moderate negative)

Signal:(33.299) Neutral

Mallinckrodt plc Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Mallinckrodt plc Correlación - Moneda/Commodity

-0.14
( neutral )

0.33
( neutral )

-0.40
( neutral )

0.46
( neutral )

-0.42
( neutral )

0.59
( weak )

Mallinckrodt plc Finanzas

Annual	2022
Ingresos:	$2.21B
Beneficio Bruto:	$891.70M (40.37 %)
EPS:	$-8.47

FY	2022
Ingresos:	$2.21B
Beneficio Bruto:	$891.70M (40.37 %)
EPS:	$-8.47

FY	2021
Ingresos:	$2.21B
Beneficio Bruto:	$891.70M (40.37 %)
EPS:	$-8.47

FY	2020
Ingresos:	$2.21B
Beneficio Bruto:	$669.40M (30.24 %)
EPS:	$-11.18

Financial Reports:

No articles found.

Mallinckrodt plc

Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, pulmonology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes; and gastrointestinal products. It offers Acthar Gel, a repository corticotropin injection for rheumatoid arthritis, infantile spasms, systemic lupus erythematosus, multiple sclerosis, systemic dermatomyositis, symptomatic sarcoidosis, severe acute and chronic allergic, and inflammatory diseases; INOmax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Therakos photopheresis, an immunotherapy treatment platform; Amitiza for constipation; and StrataGraft for the treatment of adults with deep partial-thickness burns. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; and SLN 501 is a ribonucleic acid silencing therap. In addition, it provides specialty generic drugs and active pharmaceutical ingredients. The company markets its branded products to physicians, respiratory therapists, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. Mallinckrodt plc has collaboration with Silence Therapeutics plc to develop and commercialize ribonucleic acid interference drug targets. The company was founded in 1867 and is based in Dublin, Ireland.